Crinetics Initiates Phase 3 Trial Of Paltusotine For A New Indication In Carcinoid Syndrome

Crinetics has launched CAREFNDR, a pivotal randomized double-blind Phase 3 trial of oral paltusotine (PALSONIFY) in 141 adults with carcinoid syndrome—80 mg once daily versus placebo for 16 weeks—with the primary endpoint of change in daily flushing episodes at week 12 and bowel-movement frequency as a key secondary endpoint, followed by a 104-week open-label extension to assess long-term efficacy, safety and tumor control. Paltusotine, a selective SST2 agonist already approved for acromegaly in September 2025, showed rapid, sustained symptom reductions in Phase 2, and a successful Phase 3 could broaden PALSONIFY’s label and offer an oral alternative to monthly injectable somatostatin analogs. Crinetics is also advancing an SST2-targeting oncology candidate and multiple Atumelnant studies, finished Q3 2025 with $1.1 billion cash runway into 2029, and its shares recently traded near $41.97 (-2.17%).

Analysis

Crinetics has initiated CAREFNDR, a pivotal randomized, double-blind, placebo-controlled Phase 3 trial of oral paltusotine (80 mg once daily) in 141 adults with carcinoid syndrome, with a 16-week controlled period and primary endpoint of change in daily flushing episodes at week 12 and bowel-movement frequency as a key secondary; patients then enter a 104-week open-label extension to evaluate long-term efficacy, safety and tumor control. Earlier Phase 2 data reportedly showed rapid and sustained reductions in flushing and bowel movements, supporting the trial design and the company’s strategy to extend PALSONIFY beyond its September 2025 U.S. approval for acromegaly. The program offers a clinically meaningful potential: carcinoid syndrome affects roughly 20% of neuroendocrine tumor patients and current monthly injectable somatostatin analogs often provide incomplete symptom control, so a once-daily oral SST2-targeted agent could capture market share if Phase 3 is positive. Crinetics finished Q3 2025 with $1.1 billion in cash (runway into 2029), reducing near-term financing risk, while share volatility persists (52-week range $24.10–$60.34; last close $41.97), and the stock remains exposed to binary clinical readouts and upcoming pipeline catalysts for CRN09682 and multiple Atumelnant studies.

Key Decisions for Investors

• Consider establishing a modest position to capture upside from a successful CAREFNDR outcome but size it conservatively because Phase 3 results are binary and will be value-driving
• Monitor week‑12 topline efficacy and safety data and the 104-week open‑label safety readouts as primary catalysts before materially increasing exposure, given the symptomatic endpoints and potential label expansion
• Factor in the $1.1 billion cash runway into 2029 as a de‑risking element for near‑term dilution risk, while tracking other pipeline milestones (CRN09682 and Atumelnant data/enrolment) and use hedges if holding a larger position due to expected volatility